Apollomics Inc. Warrant
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, … Read more
Apollomics Inc. Warrant (APLMW) - Total Liabilities
Latest total liabilities as of June 2024: $13.77 Million USD
Based on the latest financial reports, Apollomics Inc. Warrant (APLMW) has total liabilities worth $13.77 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Apollomics Inc. Warrant - Total Liabilities Trend (2020–2023)
This chart illustrates how Apollomics Inc. Warrant's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Apollomics Inc. Warrant Competitors by Total Liabilities
The table below lists competitors of Apollomics Inc. Warrant ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Red Capital PLC
LSE:REDC
|
UK | GBX44.80K |
|
Anglo Philippine Holdings Corp
PSE:APO
|
Philippines | ₱3.76 Billion |
|
SURNF
OTCQB:SURNF
|
USA | $34.16K |
|
Institute of Biomedical Research Corp
PINK:MRES
|
USA | $775.72K |
|
Synergia Energy Ltd.
LSE:SYN
|
UK | GBX2.36 Million |
|
DIH Holdings US, Inc. Class A Common Stock
NASDAQ:DHAI
|
USA | $63.89 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down Apollomics Inc. Warrant's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apollomics Inc. Warrant's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apollomics Inc. Warrant (2020–2023)
The table below shows the annual total liabilities of Apollomics Inc. Warrant from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $14.15 Million | -97.30% |
| 2022-12-31 | $524.60 Million | +55.99% |
| 2021-12-31 | $336.30 Million | +12.90% |
| 2020-12-31 | $297.87 Million | -- |